KPV Routes of Administration: Oral, Injectable, or Topical?

KPV is a three-amino-acid peptide, not a full-length drug, and its regulatory status is unsettled as of September 2026. Its Category 2 nomination for compounding was withdrawn by the nominators, so KPV is no longer listed in FDA Category 2 (content current 04/22/2026). Withdrawal from Category 2 is not the same as approval to compound: KPV is still not on the 503A bulks list, is not FDA-approved for any indication, and no interim enforcement discretion currently covers compounding it. On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, 1 abstain to recommend adding KPV to the 503A list, but that vote is advisory only. HHS and FDA action would still be required, and as of this writing KPV remains off the list. See the PCAC meeting record for the vote details. For a fuller regulatory walkthrough, the KPV pillar page covers the timeline in more depth.

This page's job is narrower: given that regulatory picture, what does the delivery-route evidence actually say, and does it differ meaningfully by route.

Why does the oral route get the most attention in the KPV literature?

KPV is a tripeptide, and tripeptides are the natural substrate class for PepT1 (peptide transporter 1), a transporter expressed on intestinal epithelial cells. Early work established that PepT1-mediated uptake of KPV reduces intestinal inflammation in cell and animal models of colitis (Gastroenterology, 2008). That single mechanistic fact, that KPV can piggyback on a transporter your gut already uses to absorb dietary peptides, is why so much subsequent research effort went into oral and colon-targeted delivery systems rather than injection.

The pattern held over the following quinnium: melanocortin-derived KPV showed anti-inflammatory potential in murine inflammatory bowel disease models (Inflammatory Bowel Diseases, 2008), and a 2016 paper went further, showing that PepT1 itself plays a role in promoting colitis-associated cancer in mice, with PepT1-mediated KPV delivery offering measurable therapeutic benefit in that same murine model (Cellular and Molecular Gastroenterology and Hepatology, 2016). Since then, most of the engineering effort has gone into getting KPV to survive the GI tract intact and concentrate at the site of colonic inflammation rather than degrading before it gets there: polysaccharide hydrogel nanoparticles targeted to the colon reduced colitis in mice (Gastroenterology, 2010), hyaluronic acid-functionalized nanoparticles improved oral delivery efficiency in a rodent ulcerative colitis model (Molecular Therapy, 2017), and more recent formulations have used self-immolative conjugates designed specifically to survive the gastrointestinal barrier for oral peptide delivery (Science Advances, 2026).

This is a substantial and consistent body of drug-delivery science. It is also, without exception in the sources reviewed here, animal-model and in-vitro work. No human oral KPV trial data appears in the evidence base cited on this page. The honest statement is: the biological rationale for oral absorption is unusually well worked out for a peptide this small, but "well worked out in mice" is not the same claim as "shown to work in people." Readers looking at oral KPV for gut conditions should see the KPV and IBD/ulcerative colitis page for how this evidence maps onto specific GI use cases, and the boundary is the same there: mechanism and animal efficacy, not human trial data.

What does the evidence say about injectable KPV?

Less than for oral. The PepT1 mechanism that makes oral delivery biologically interesting is specific to the gut lumen and epithelium; it does not describe what happens to KPV once it is injected into subcutaneous tissue or muscle. None of the sources in this evidence base directly study injectable KPV pharmacokinetics, tissue distribution, or clinical outcomes. Some compounding pharmacies formulate and dispense injectable KPV as part of broader peptide practice, but that is a description of current compounding activity, not a claim about supporting trial evidence. Where injectable KPV protocols exist in clinical practice, they should be treated as unsourced clinical practice rather than evidence-backed dosing, and readers should not infer efficacy or safety data that the literature does not contain. For general dosing and administration considerations across routes, see the KPV dosing page; for systemic (non-topical) use patterns specifically, see KPV systemic use.

What does the evidence say about topical KPV for skin?

Topical use is the route with the thinnest direct support in this evidence set. The melanocortin system, of which KPV is a fragment, has documented roles in skin and mucosal inflammation, and a 2023 review lays out the broader mechanistic case for melanocortin-pathway involvement in inflammatory bowel disease specifically, not skin (Cells, 2023). None of the sources reviewed here are dermal absorption, skin-barrier penetration, or topical-formulation studies of KPV. That does not mean topical KPV cannot work, only that this page cannot point to delivery-specific evidence supporting skin penetration or topical efficacy the way it can for the oral-gut axis. Readers interested in eczema or psoriasis applications should treat topical KPV claims as unproven pending dermal-specific data, and the KPV and eczema/psoriasis page and the KPV versus topical steroid comparison go into what is and is not established for skin use in more detail.

So which route is best supported?

Ranked strictly by the delivery-mechanism and delivery-engineering evidence reviewed here, oral (specifically PepT1-mediated, colon-targeted oral delivery) has by far the most direct support, all of it preclinical. Injectable use has essentially no route-specific evidence in this literature; its rationale rests on general peptide pharmacology rather than KPV-specific injection data. Topical use has the least direct evidence of the three. This ranking is about delivery mechanism, not about which route is safest or most appropriate to use, since none of the three has human efficacy trial data and none of the three has an FDA-approved status to lean on.

A route-evidence checklist, not a recommendation

Before treating any claim about a specific KPV delivery route as settled, it is worth running it through four questions:

1. Is the cited evidence about this exact route, or borrowed from a different one? Oral-absorption data (PepT1 uptake) does not transfer to injectable or topical claims, and vice versa.
2. Is the model animal, in-vitro, or human? Every delivery-route study in the current KPV literature reviewed here is preclinical. A claim phrased as if it were human data is a red flag.
3. Is the endpoint efficacy, or just delivery/targeting? Many of the newer studies (hydrogels, nanoparticles, fluorescent probes) measure whether KPV reaches the target tissue, not whether it changes a clinical outcome in a person.
4. Does the source predate or postdate the PCAC vote and the Category 2 withdrawal? Regulatory status has moved twice in 2026; older summaries may describe a status that no longer applies.

What is established, what is plausible, and what is not established

Established: KPV is a PepT1 substrate, and PepT1-mediated uptake reduces markers of intestinal inflammation in mouse colitis models across multiple independent research groups and formulation approaches spanning 2008 through 2026. Plausible but unproven: that this preclinical oral-delivery advantage translates into a clinically meaningful effect in humans, since no human trial data appears in the sources reviewed here. Not established: that injectable or topical KPV delivery has any route-specific efficacy or safety evidence comparable to the oral-PepT1 literature, and not established: that any route of KPV administration is FDA-approved or currently compoundable under a confirmed 503A pathway as of September 2026.

If you are already using or considering KPV through a compounding source, ask the pharmacy directly what route-specific evidence they are relying on, and treat any claim of "FDA-recognized" or "approved for compounding" as inaccurate until KPV actually appears on the 503A bulks list. Seek urgent medical care rather than adjusting a peptide regimen yourself if you develop signs of a serious reaction, such as difficulty breathing, facial swelling, or severe abdominal pain after any KPV administration route.